<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JHS</journal-id>
<journal-id journal-id-type="hwp">spjhs</journal-id>
<journal-id journal-id-type="nlm-ta">J Hand Surg Eur Vol</journal-id>
<journal-title>Journal of Hand Surgery (European Volume)</journal-title>
<issn pub-type="ppub">1753-1934</issn>
<issn pub-type="epub">2043-6289</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1753193411427826</article-id>
<article-id pub-id-type="publisher-id">10.1177_1753193411427826</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Full length articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Tolerance and effects of FK506 (tacrolimus) on nerve regeneration: a pilot study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Phan</surname><given-names>D. Q. D.</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Schuind</surname><given-names>F.</given-names></name>
</contrib>
<aff id="aff1-1753193411427826">Service d’Orthopédie-Traumatologie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, Brussels, Belgium</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1753193411427826">F. Schuind, Service d’Orthopédie-Traumatologie, Cliniques Universitaires de Bruxelles, Hôpital Erasme, 808 Route de Lennik, B-1070 Brussels, Belgium Email: <email>Frederic.Schuind@erasme.ulb.ac.be</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2012</year>
</pub-date>
<volume>37</volume>
<issue>6</issue>
<fpage>537</fpage>
<lpage>543</lpage>
<history>
<date date-type="received">
<day>27</day>
<month>4</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>26</day>
<month>9</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>10</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">The British Society for Surgery of the Hand</copyright-holder>
</permissions>
<abstract>
<p>In adults, the outcome of nerve suture and nerve autograft remains generally unsatisfactory. FK506 (tacrolimus), an immunosuppressant drug used in transplantation, has been reported in animal studies to enhance nerve regeneration. In hand transplantation patients, nerve regeneration was unexpectedly good and rapid, and this observation has been attributed to FK506. The present Phase II experiment investigated the tolerance to FK506 after nerve suture or autograft, and the potential effects of the drug on axonal regeneration. Following strict criteria, five patients were included in this study. Within 7 days of nerve repair (median, ulnar and sciatic transections), patients received FK506 (aiming for blood concentrations between 5 and 8 ng/ml) for a total duration of 60 days. The patients were carefully followed with clinical and biological monitoring in order to detect side-effects. A clinical and electrophysiological assessment of the effect of FK506 on nerve regeneration was conducted. No undesirable side-effect was observed during or after FK506 treatment, but one non-compliant patient discontinued treatment. There was no evident improvement of sensory, motor or functional recovery at the end of the follow-up period (average duration 39.8 months), as compared to the expected clinical result without treatment. Although statistically non-significant, FK506 seemed to accelerate the progression of the Hoffmann–Tinel sign, but without impact on the final result.</p>
</abstract>
<kwd-group>
<kwd>Nerve suture</kwd>
<kwd>nerve graft</kwd>
<kwd>FK506</kwd>
<kwd>tacrolimus</kwd>
<kwd>axonal regeneration</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1753193411427826" sec-type="intro">
<title>Introduction</title>
<p>In spite of the enormous developments in neurosciences and the various refinements in surgical techniques, there has been no major improvement in the clinical results of nerve suture or nerve graft (<xref ref-type="bibr" rid="bibr24-1753193411427826">Lundborg, 2000</xref>). Many patients are left with some palsy, severe sensory problems and/or persistent neuropathic pain. New ways to improve axonal regeneration are needed (<xref ref-type="bibr" rid="bibr34-1753193411427826">Schuind et al., 2011</xref>).</p>
<p>FK506 (tacrolimus, Prograft<sup>®</sup>, previously supplied by Fujisawa Co., now Astellas Pharma, Tokyo, Japan), a macrolide lactone with immunosuppressive activity (potent inhibitor of calcineurin), has been used since 1992 in renal and hepatic transplantation, and later also in hand transplantation (<xref ref-type="bibr" rid="bibr33-1753193411427826">Schuind et al., 2007</xref>). In addition to its immunosuppressive action, FK506 has been reported to enhance axonal regeneration, an unexpected effect as at high doses FK506 is neurotoxic. In human hand transplantation, nerve regeneration has been unexpectedly good and quick, possibly better than after replantation, and this observation has been attributed to the beneficial effects on nerve regeneration of FK506. In our case of hand transplantation in Brussels, with 8.5 years of follow-up, we observed a rate of progression of the Hoffmann–Tinel sign of 3 mm per day, excellent sensory recovery with two-point discrimination in the pulps of thumb and index of 6 mm, and restoration of functioning intrinsic muscles (<xref ref-type="bibr" rid="bibr32-1753193411427826">Schuind et al., 2006</xref>). <xref ref-type="bibr" rid="bibr25-1753193411427826">Martin et al. (2005)</xref> reported a case of a proximal arm replantation in a 60-year-old female with an “exceptional” neurological recovery, after 1 year of FK506 treatment. In experimental nerve allografting in animals, FK506 has been demonstrated to improve graft survival (<xref ref-type="bibr" rid="bibr1-1753193411427826">Alemdar et al., 2001</xref>) and to favour axonal regeneration (<xref ref-type="bibr" rid="bibr17-1753193411427826">Grand et al., 2002</xref>; <xref ref-type="bibr" rid="bibr29-1753193411427826">Navarro et al., 2001</xref>; <xref ref-type="bibr" rid="bibr31-1753193411427826">Rustemeyer et al., 2009</xref>, <xref ref-type="bibr" rid="bibr30-1753193411427826">2010</xref>). FK506 has also been demonstrated in animals to enhance nerve regeneration after peripheral nerve suture, end-to-side neurotization, nerve autograft, peripheral nerve crush, and even after spinal cord transection (<xref ref-type="bibr" rid="bibr3-1753193411427826">Bain, 2000</xref>; <xref ref-type="bibr" rid="bibr7-1753193411427826">Brenner et al., 2005</xref>; <xref ref-type="bibr" rid="bibr9-1753193411427826">Büttemeyer et al., 1995</xref>; <xref ref-type="bibr" rid="bibr10-1753193411427826">Chunasuwankul et al., 2002</xref>; <xref ref-type="bibr" rid="bibr13-1753193411427826">Doolabh and Mackinnon, 1999</xref>; <xref ref-type="bibr" rid="bibr18-1753193411427826">Hontanilla et al., 2006</xref>; <xref ref-type="bibr" rid="bibr21-1753193411427826">Jifeng et al., 2010</xref>; <xref ref-type="bibr" rid="bibr22-1753193411427826">Konofaos et al., 2010</xref>; <xref ref-type="bibr" rid="bibr23-1753193411427826">Lee et al., 2000</xref>; <xref ref-type="bibr" rid="bibr42-1753193411427826">Yildirim et al., 2008</xref>). Several authors suggested also that under FK506 axonal regeneration was quicker (<xref ref-type="bibr" rid="bibr8-1753193411427826">Brenner et al., 2008</xref>; <xref ref-type="bibr" rid="bibr38-1753193411427826">Terzis and Konofaos, 2010</xref>). FK506 also seems effective in vascular inflammatory-related neuropathic pain (<xref ref-type="bibr" rid="bibr27-1753193411427826">Muthuraman and Sood, 2010</xref>). Based on these findings, further study of the prospect of using FK506, for a limited time, to “boost” axonal regeneration following conventional nerve suture or nerve graft would seem a good idea. However, there is toxicity associated with the use of FK506. Compared to cyclosporine the incidence of arterial hypertension, hypercholesterolemia, and renal insufficiency is lower, but there is a higher incidence of disturbances in glucose metabolism and some types of neurotoxicity. In addition, there is an increased risk of malignancies, as with all immunosuppressive agents. Close monitoring and adjustment of the drug’s blood concentrations is vital.</p>
<p>The aims of this “proof of concept” type of study were to evaluate in humans the effects of FK506 after conventional repair of ordinary nerve lesions. Specifically, the purpose of this Phase II open prospective study was to evaluate the general tolerance of 2 months of oral FK506 medication at transplantation dosages after nerve repair, and to assess the speed and quality of nerve regeneration under and after FK506 treatment. In the case of obvious effects, this pilot study would then be pursued by a prospective randomized comparative trial.</p>
</sec>
<sec id="section2-1753193411427826" sec-type="materials|methods">
<title>Materials and methods</title>
<p>The study was approved by our Institution Ethics Committee. FK506 was supplied by Fujisawa Company. Following the strict inclusion and exclusion criteria presented in <xref ref-type="table" rid="table1-1753193411427826">Table 1</xref>, six patients were enrolled in the study. All patients were active in their own profession. One of these patients was excluded after 1 week because of poor compliance. Another stopped treatment after 1 month. During the period of inclusion, at least 30 other patients could not be included, mainly because either the nerve lesion was too extensive with an avulsive mechanism (brachial plexus), because of poor patient compliance, or because of abnormal glucose metabolism, or because the patient was unwilling to participate in the study.</p>
<table-wrap id="table1-1753193411427826" position="float">
<label>Table 1.</label>
<caption>
<p>Inclusion and exclusion criteria</p>
</caption>
<graphic alternate-form-of="table1-1753193411427826" xlink:href="10.1177_1753193411427826-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Inclusion criteria</th>
<th align="left">Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adult patient (&gt;18 years)</td>
<td>&lt;18 years</td>
</tr>
<tr>
<td>Mentally able to understand the protocol</td>
<td>Psychological or general neurological problems</td>
</tr>
<tr>
<td rowspan="2">Simple total nerve section of a major nerve of the arm, forearm or leg</td>
<td>Major skin defect</td>
</tr>
<tr>
<td>Avulsive mechanism of nerve injury</td>
</tr>
<tr>
<td rowspan="2">Microsurgical suture or graft by hand specialist, within 10 days of trauma (or within 4 months in case of nerve graft)</td>
<td>Nerve defect obliging to suture under tension</td>
</tr>
<tr>
<td>Polytraumatism</td>
</tr>
<tr>
<td>Primary closure of the wound, no infection</td>
<td>Concomitant peripheral nerve affection</td>
</tr>
<tr>
<td/>
<td>Arterial hypertension</td>
</tr>
<tr>
<td/>
<td>Abnormal renal function (serum creatinine &gt;1.5 mg/100 ml)</td>
</tr>
<tr>
<td/>
<td>Hyperlipidaemia</td>
</tr>
<tr>
<td/>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td/>
<td>Patient under treatment by glucose-lowering drugs</td>
</tr>
<tr>
<td/>
<td>Concomitant immunosuppressive or steroid treatment</td>
</tr>
<tr>
<td/>
<td>Pregnancy</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Within 7 days of nerve repair of a simple transection, by suture performed within 10 days of the trauma, or by nerve graft done within 4 months of the initial lesion, the patients received oral FK506 (aiming at blood concentrations between 5 and 8 ng/ml) for a total of 60 days. Patients received an initial dose of 0.075 mg/kg per day (divided into two intakes per day), and the oral dose was adjusted based on the blood concentrations, monitored twice a week for the first 2 weeks, then once a week for the next 2 weeks, and finally every other week until the end of the 2 months. In addition to the monitoring of the FK506 blood concentrations, the patients were carefully followed clinically and biologically in order to detect possible side-effects: blood samples measured fasting glucose, glycosylated haemoglobin (D0 and D60), urea, creatinine, ionogram, CRP, LDH and haematological count. FK506 was to be discontinued in cases of arterial hypertension, diabetes mellitus, decreased renal function or other significant complication.</p>
<p>The clinical assessment of nerve regeneration was performed by an independent observer who followed the progression of the Hoffmann–Tinel sign, the recovery of sensibility (touch-test, two-point discrimination, Semmes–Weinstein monofilaments) and of active motion (analytical muscle testing, grip and pinch strengths, evaluation of possible persistent amyotrophy). The Hoffmann–Tinel sign was performed by lightly tapping over the distal segment of the repaired nerve, starting distal and progressing proximally, to elicit the first point of a sensation of tingling in the dermatome of the considered nerve. Questionnaires were also used at the end of the follow-up to assess global function and quality of life: disabilities of the arm, shoulder and hand (DASH) for the upper extremity (<xref ref-type="bibr" rid="bibr19-1753193411427826">Hudak et al., 1996</xref>; <xref ref-type="bibr" rid="bibr20-1753193411427826">Jester et al., 2005</xref>), LEFS (Lower Extremity Functional Scale; <xref ref-type="bibr" rid="bibr4-1753193411427826">Binkley et al., 1999</xref>) for the lower extremity. Neuropathic pain or clinical signs of complex regional pain syndrome (CRPS) were reported. In addition, all patients had electrophysiological assessments on a regular basis by independent neurologists.</p>
<p>The one-sample Student’s <italic>t</italic>-test was used for statistical analysis of the speed of the Hoffmann–Tinel sign, with <italic>p</italic> &lt; 0.05 considered as significant (SPSS v19).</p>
</sec>
<sec id="section3-1753193411427826" sec-type="results">
<title>Results</title>
<p>The average follow-up was 39.8 months (SD 11 months; range 23–48 months). Four of the five patients had a nerve transection in the upper extremity (two ulnar, one radial and one median nerve) and one in the thigh (sciatic nerve, <xref ref-type="table" rid="table2-1753193411427826">Table 2</xref>). The lesion of the median nerve was iatrogenic during a trapeziectomy in a dysmorphic wrist; it was the only partial section in the series.</p>
<table-wrap id="table2-1753193411427826" position="float">
<label>Table 2.</label>
<caption>
<p>Patients</p>
</caption>
<graphic alternate-form-of="table2-1753193411427826" xlink:href="10.1177_1753193411427826-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Patient</th>
<th align="left">Gender</th>
<th align="left">Age (years)</th>
<th align="left">Past medical history</th>
<th align="left">Nerve lesion, side, location</th>
<th align="left">% of section</th>
<th align="left">Nerve repair</th>
<th align="left">Follow-up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>43</td>
<td>TM OA</td>
<td>Median, R, carpal tunnel</td>
<td>70</td>
<td>Graft</td>
<td>48</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>40</td>
<td>Tenopathy</td>
<td>Ulnar, R, forearm</td>
<td>100</td>
<td>Suture</td>
<td>46</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>30</td>
<td>None</td>
<td>Ulnar, R, forearm</td>
<td>100</td>
<td>Graft</td>
<td>39</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>28</td>
<td>None</td>
<td>Sciatic, L, thigh</td>
<td>100</td>
<td>Suture</td>
<td>19</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>22</td>
<td>None</td>
<td>Radial, R, arm</td>
<td>100</td>
<td>Suture</td>
<td>34</td>
</tr>
<tr>
<td>Mean, SD</td>
<td>Men 60%</td>
<td>32.6 (7.8)</td>
<td/>
<td>Upper extremity 80%</td>
<td>94 (12)</td>
<td>Suture 60%</td>
<td>39.8 (11)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1753193411427826">
<p>TM OA: trapezio-metacarpal osteoarthrosis.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section4-1753193411427826">
<title>Tolerance to FK506</title>
<p>No undesirable side-effects were observed during or after treatment, or at the end of the follow-up. However, patient 5 with poor compliance discontinued the treatment after 1 month and could not be later assessed for the progression of the Hoffmann–Tinel sign; he could, however, be clinically evaluated at 34 months.</p>
</sec>
<sec id="section5-1753193411427826">
<title>Progression of the Hoffmann–Tinel sign</title>
<p>The average progression (patients 1, 2, 3 and 4) was 0.62 mm/day during the 2 months of treatment (SD 0.34 mm/day; range 0–1.6 mm/day), after FK506 discontinuation 1.97 mm/day (SD 0.69 mm/day; range 0.3–3.6 mm/day); the mean progression of the Hoffmann–Tinel sign during the whole post-operative period was 1.4 mm/day (SD 0.42 mm/day; range 0.33–2.37 mm/day; <xref ref-type="table" rid="table3-1753193411427826">Table 3</xref>). These values were non-significant as compared to the classical reference value of 1 mm/day (<italic>p</italic> &gt; 0.05).</p>
<table-wrap id="table3-1753193411427826" position="float">
<label>Table 3.</label>
<caption>
<p>Results</p>
</caption>
<graphic alternate-form-of="table3-1753193411427826" xlink:href="10.1177_1753193411427826-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2">Patient</th>
<th align="left" rowspan="2">Lesion</th>
<th align="left" rowspan="2">Tolerance to FK506 treatment</th>
<th align="left" colspan="3">Progression of Hoffmann–Tinel sign</th>
<th align="left" colspan="7">Result at end of follow-up</th>
</tr>
<tr>
<th align="left">During FK506 treatment</th>
<th align="left">After FK506 treatment</th>
<th align="left">Whole period of nerve regeneration</th>
<th align="left"><italic>Sensibility</italic></th>
<th align="left">Motricity (Medical Research Council)</th>
<th align="left">Pain</th>
<th align="left">Conduction potentials and velocities</th>
<th align="left">EMG</th>
<th align="left">DASH</th>
<th align="left">LEFS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Partial median, graft</td>
<td>Excellent</td>
<td>0.5</td>
<td>3.6</td>
<td>1.5</td>
<td>S3</td>
<td>M5</td>
<td>Moderate dysesthesiae</td>
<td>Marked improvement</td>
<td>Improvement</td>
<td>36.7</td>
<td/>
</tr>
<tr>
<td>2</td>
<td>Total ulnar, suture</td>
<td>Excellent</td>
<td>1.6</td>
<td>0.3</td>
<td>0.33</td>
<td>S3</td>
<td>M5</td>
<td>Moderate allodynia and contact dysesthesiae</td>
<td>Marked improvement</td>
<td>Improvement</td>
<td>9.2</td>
<td/>
</tr>
<tr>
<td>3</td>
<td>Total ulnar, graft</td>
<td>Excellent</td>
<td>0.4</td>
<td>1.6</td>
<td>1.4</td>
<td>S3</td>
<td>M3</td>
<td>Moderate contact dysesthesiae</td>
<td>Marked improvement</td>
<td>No improvement</td>
<td>19.2</td>
<td/>
</tr>
<tr>
<td>4</td>
<td>Total sciatic, suture</td>
<td>Excellent</td>
<td>0</td>
<td>2.4</td>
<td>2.37</td>
<td>S2</td>
<td>M4</td>
<td>Contact dysesthesiae</td>
<td>Marked improvement</td>
<td>Improvement</td>
<td/>
<td>24</td>
</tr>
<tr>
<td>5</td>
<td>Total radial, suture</td>
<td>Non-compliance, discontinuation of FK506 (second month)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>S3+</td>
<td>M3–M5 (according to tested muscle)</td>
<td>Important dysesthesiae</td>
<td>No data</td>
<td>No data</td>
<td>15</td>
<td/>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section6-1753193411427826">
<title>Recovery of sensibility</title>
<p>All patients recovered protective sensation; none however demonstrated discriminative sensibility with two-point discrimination &lt;10 mm (<xref ref-type="table" rid="table3-1753193411427826">Table 3</xref>).</p>
</sec>
<sec id="section7-1753193411427826">
<title>Motor recovery</title>
<p>There was evidence of incomplete motor recovery in all patients (<xref ref-type="table" rid="table3-1753193411427826">Table 3</xref>).</p>
</sec>
<sec id="section8-1753193411427826">
<title>Pain</title>
<p>All patients suffered persistent dysesthesiae of variable intensity; none presented any sign of CRPS.</p>
</sec>
<sec id="section9-1753193411427826">
<title>Return to work</title>
<p>All patients resumed their previous professional occupations.</p>
</sec>
<sec id="section10-1753193411427826">
<title>Electromyograms and conduction velocities</title>
<p>The patient with poor compliance (patient 5) refused all neurophysiological examinations in his follow-up, accepting only clinical evaluations. In all other patients, conduction potentials and velocities markedly improved; the electromyograms showed evidence of muscular reinnervation, except in patient 3.</p>
</sec>
<sec id="section11-1753193411427826">
<title>Questionnaires</title>
<p>For the upper extremity nerve repairs, the mean DASH was 20.0 (SD 10.3). For the sciatic nerve suture, the LEFS was 12 (27.5% of normal).</p>
</sec>
</sec>
<sec id="section12-1753193411427826" sec-type="discussion">
<title>Discussion</title>
<p>The clinical results after peripheral nerve suture or graft are frequently disappointing, particularly in adults. In animals, FK506 has been demonstrated to enhance nerve regeneration. Good nerve regeneration has also been reported in hand transplantation cases, possibly related to FK506, one of the immunosuppressant drugs prescribed in most of these patients. The immunosuppressant activity of FK506 is related to its binding with an immunophilin, FKBP-12 (FK-binding protein 12), inhibiting calcineurin and, by chain reaction, decreasing the proliferation of the lymphocytes. This pathway does not, however, seem to be involved in the neuroregenerative properties (<xref ref-type="bibr" rid="bibr14-1753193411427826">Gold et al., 1999</xref>). The binding of FK506 with another immunophilin, FKPB-52, leads to the activation of several others pathways. One of the most studied is in relationship with the increase of GAP-43/B50 synthesis, which stimulates axonal sprouting and the activity of the growth cone by interacting with its actin microfilaments (<xref ref-type="bibr" rid="bibr16-1753193411427826">Gold et al., 1998</xref>; <xref ref-type="bibr" rid="bibr40-1753193411427826">Udina et al., 2002</xref>). Others pathways are also involved but are still unclear: some of them imply interactions with microtubules, microfilaments, dyenins and kinesins, which could influence the retrograde axonal transport and cytoskeleton modifications essential in axonal growth and neuronal survival (<xref ref-type="bibr" rid="bibr43-1753193411427826">Zochodne, 2008</xref>). The activation of several other biochemical pathways involving different kinds of kinases and receptors regulating the intracellular calcium flux could also play a role in signal transduction of growth factors. The immunophilin’s ligand as FK506 could therefore, by several complex pathways, increase the number and the maturity of the axons during regeneration and stimulate collateral sprouting (<xref ref-type="bibr" rid="bibr43-1753193411427826">Zochodne, 2008</xref>). In addition to these neuroregenerative effects, FK506 possesses brain-protective effects (<xref ref-type="bibr" rid="bibr12-1753193411427826">Dawson et al., 1993</xref>), is efficient in inflammatory neuropathies (<xref ref-type="bibr" rid="bibr15-1753193411427826">Gold et al., 2004</xref>) and in cerebral ischaemia (<xref ref-type="bibr" rid="bibr35-1753193411427826">Sharkey and Butcher, 1994</xref>); in transplantation, FK506 protects the muscles from ischaemia-reperfusion lesions (<xref ref-type="bibr" rid="bibr2-1753193411427826">Askar and Bozkurt, 2002</xref>; <xref ref-type="bibr" rid="bibr5-1753193411427826">Black et al., 1987</xref>; <xref ref-type="bibr" rid="bibr26-1753193411427826">Mowlavi et al., 2001</xref>).</p>
<p>Based on the better nerve regeneration in animals, and on the experience in hand transplantation, it seemed reasonable to investigate whether FK506 could improve the clinical results after conventional nerve suture and nerve graft. Before initiating a prospective randomized trial with placebo control, and given that FK506 is quite a toxic drug, the first step was to perform a pilot Phase II study, with the aim of evaluating the tolerance to this treatment, and to detect possible improvement of the clinical results. No side-effects or complications were observed under close monitoring of blood concentrations, but one patient ceased after 1 week and another after 1 month, proving to be non-compliant, probably in relationship to the number of medical visits and blood tests. Concerning the neurological recovery, we unfortunately did not observe by the end of the follow-up in our five cases any dramatic improvement in sensory, motor or functional recovery, when compared to the expected recovery without FK506 administration. Although statistically non-significant, FK506 seemed to slightly accelerate the progression of the Hoffmann–Tinel sign (average 1.4 mm/day), without impact on the final result. In our statistical analysis, we considered as the reference value a speed of progression of 1 mm/day. This classical value, reported by <xref ref-type="bibr" rid="bibr39-1753193411427826">Tinel (1915)</xref>, is poorly documented in the literature. <xref ref-type="bibr" rid="bibr37-1753193411427826">Sunderland (1947)</xref> cited this speed (as assessed in only 4.3% of his patients) in type III lesions (axonotmesis following Seddon), rather than after nerve transection and repair. <xref ref-type="bibr" rid="bibr6-1753193411427826">Bourcheix and Masmejean (2011)</xref> observed that the rate of progression of the Hoffmann–Tinel sign is slower in cases of nerve suture or nerve graft, and proposed that one should add 4–8 weeks for the passage through the zone of nerve suture. <xref ref-type="bibr" rid="bibr28-1753193411427826">Napier (1949)</xref> reported faster rates of progression of up to 2–3 mm/day in cases ending with a good recovery, but his series included partial nerve sections. The Hoffmann–Tinel sign has been controversial since its first description 100 years ago, as its presence is not always associated with a functional recuperation, and the assessment remains quite subjective, particularly as dysesthesiae and allodynia can be misinterpreted as a positive Hoffmann–Tinel sign (<xref ref-type="bibr" rid="bibr11-1753193411427826">Davis and Chung, 2004</xref>).</p>
<p>The lack of improved neurological recovery could be due to our protocol of FK506 administration being less than optimal. We used FK506 at transplantation dosages, while <xref ref-type="bibr" rid="bibr40-1753193411427826">Udina et al. (2002)</xref> demonstrated in mice that FK506 has a bimodal action, with efficacy on nerve regeneration at lower concentrations during the first week of treatment. Our patients had 2 months of treatment, while <xref ref-type="bibr" rid="bibr41-1753193411427826">Udina et al. (2004)</xref> suggested, based on their animal studies, a shorter treatment period. We started the treatment within the first week after the nerve suture or the nerve graft, while <xref ref-type="bibr" rid="bibr36-1753193411427826">Snyder et al. (2006)</xref> reported that FK506 should be given before the nerve lesion.</p>
<p>If FK506 does not markedly increase axonal regeneration, how to explain the remarkable sensory recovery observed in hand transplanted patients? In these patients, FK506 was started earlier and continued beyond 2 months. Other factors could also be important, such as the lack of tension in nerve repairs in transplantation, and the intensive physiotherapy that all hand transplantation patients received (our case in Brussels had 3 hours of physiotherapy every day initially).</p>
</sec>
<sec id="section13-1753193411427826" sec-type="conclusions">
<title>Conclusion</title>
<p>This human Phase II study on conventional nerve sutures and grafts did not demonstrate any evidence that FK506 (tacrolimus, Prograft®) enhances nerve regeneration. However the treatment proved to be safe, provided that meticulous monitoring was performed. The level of monitoring was not accepted by all patients. The frustrating conclusion, that FK506 does not evidently improve the results after conventional nerve repair, should be interpreted with caution however, because this study is based on a limited heterogeneous series. It could be that the delay in commencing treatment (within 1 week of nerve repair) and the duration of treatment (60 days) were not optimal. Further studies of the protocol of administration and efficacy of the drug in peripheral nerve injuries are needed.</p>
</sec>
</body>
<back>
<ack>
<p>The authors wish to acknowledge the contribution of Mrs F. Moulart as data manager for the first patients included in the study.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This work was partly supported by Fujisawa Company (now Astellas Pharma, Tokyo, Japan) (supply of tacrolimus).</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interests</label>
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alemdar</surname><given-names>AY</given-names></name>
<name><surname>Baker</surname><given-names>KA</given-names></name>
<name><surname>Sadi</surname><given-names>D</given-names></name>
<name><surname>McAlister</surname><given-names>VC</given-names></name>
<name><surname>Mendez</surname><given-names>I</given-names></name>
</person-group>. <article-title>Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats</article-title>. <source>Exp Neurol</source>. <year>2001</year>, <volume>172</volume>: <fpage>416</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr2-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Askar</surname><given-names>I</given-names></name>
<name><surname>Bozkurt</surname><given-names>M</given-names></name>
</person-group>. <article-title>Protective effects of immunosuppressants and steroids against ischemia-reperfusion injury in cremaster muscle flap at microcirculatory level</article-title>. <source>Microsurgery</source>. <year>2002</year>, <volume>22</volume>: <fpage>361</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr3-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bain</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Peripheral nerve and neuromuscular allotransplantation: current status</article-title>. <source>Microsurgery</source>. <year>2000</year>, <volume>20</volume>: <fpage>384</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr4-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Binkley</surname><given-names>JM</given-names></name>
<name><surname>Stratford</surname><given-names>PW</given-names></name>
<name><surname>Lott</surname><given-names>SA</given-names></name>
<name><surname>Riddle</surname><given-names>DL</given-names></name>
</person-group>. <article-title>The Lower Extremity Functional Scale (LEFS): scale development, measurement properties, and clinical application</article-title>. <source>Phys Ther</source>. <year>1999</year>, <volume>79</volume>: <fpage>371</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr5-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Black</surname><given-names>KS</given-names></name>
<name><surname>Hewitt</surname><given-names>CW</given-names></name>
<name><surname>Henson</surname><given-names>LE</given-names></name>
<name><surname>Chau</surname><given-names>LC</given-names></name>
<name><surname>Pizzo</surname><given-names>L</given-names></name>
<name><surname>Achauer</surname><given-names>BM</given-names></name>
</person-group>. <article-title>Cyclosporine-induced long-term allograft survival and its potential in posttrauma tissue replacement</article-title>. <source>J Burn Care Rehabil</source>. <year>1987</year>, <volume>8</volume>: <fpage>531</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr6-1753193411427826">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Bourcheix</surname><given-names>L</given-names></name>
<name><surname>Masmejean</surname><given-names>E</given-names></name>
</person-group>. <article-title>Anatomie pathologique, classifications, régénération du nerf traumatisé</article-title>. In: <person-group person-group-type="editor">
<name><surname>Fontaine</surname><given-names>C</given-names></name>
<name><surname>Liverneaux</surname><given-names>P</given-names></name>
<name><surname>Masmejean</surname><given-names>E</given-names></name>
</person-group> (eds) <source>Cours européen de pathologie chirurgicale du membre supérieur et de la main 2011</source>. <publisher-loc>Montpellier</publisher-loc>: <publisher-name>Sauramps</publisher-name>, <year>2011</year>: <fpage>314</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr7-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brenner</surname><given-names>MJ</given-names></name>
<name><surname>Mackinnon</surname><given-names>SE</given-names></name>
<name><surname>Rickman</surname><given-names>SR</given-names></name>
<etal/>
</person-group>. <article-title>FK506 and anti-CD40 ligand in peripheral nerve allotransplantation</article-title>. <source>Restor Neurol Neurosci</source>. <year>2005</year>, <volume>23</volume>: <fpage>237</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr8-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brenner</surname><given-names>MJ</given-names></name>
<name><surname>Moradzadeh</surname><given-names>A</given-names></name>
<name><surname>Myckatyn</surname><given-names>TM</given-names></name>
<etal/>
</person-group>. <article-title>Role of timing in assessment of nerve regeneration</article-title>. <source>Microsurgery</source>. <year>2008</year>, <volume>28</volume>: <fpage>265</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr9-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Büttemeyer</surname><given-names>R</given-names></name>
<name><surname>Rao</surname><given-names>U</given-names></name>
<name><surname>Jones</surname><given-names>NF</given-names></name>
</person-group>. <article-title>Peripheral nerve allograft transplantation with FK506: functional, histological, and immunological results before and after discontinuation of immunosuppression</article-title>. <source>Ann Plast Surg</source>. <year>1995</year>, <volume>35</volume>: <fpage>396</fpage>–<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr10-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chunasuwankul</surname><given-names>R</given-names></name>
<name><surname>Ayrout</surname><given-names>C</given-names></name>
<name><surname>Dereli</surname><given-names>Z</given-names></name>
<name><surname>Gal</surname><given-names>A</given-names></name>
<name><surname>Lanzetta</surname><given-names>M</given-names></name>
<name><surname>Owen</surname><given-names>E</given-names></name>
</person-group>. <article-title>Low dose discontinued FK506 treatment enhances peripheral nerve regeneration</article-title>. <source>Int Surg</source>. <year>2002</year>, <volume>87</volume>: <fpage>274</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr11-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>EN</given-names></name>
<name><surname>Chung</surname><given-names>KC</given-names></name>
</person-group>. <article-title>The Tinel sign: a historical perspective</article-title>. <source>Plast Reconstr Surg</source>. <year>2004</year>, <volume>114</volume>: <fpage>494</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr12-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dawson</surname><given-names>TM</given-names></name>
<name><surname>Steiner</surname><given-names>JP</given-names></name>
<name><surname>Dawson</surname><given-names>VL</given-names></name>
<etal/>
</person-group>. <article-title>Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1993</year>, <volume>90</volume>: <fpage>9808</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr13-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Doolabh</surname><given-names>VB</given-names></name>
<name><surname>Mackinnon</surname><given-names>SE</given-names></name>
</person-group>. <article-title>FK506 accelerates functional recovery following nerve grafting in a rat model</article-title>. <source>Plast Reconstr Surg</source>. <year>1999</year>, <volume>103</volume>: <fpage>1928</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr14-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gold</surname><given-names>BG</given-names></name>
<name><surname>Densmore</surname><given-names>V</given-names></name>
<name><surname>Shou</surname><given-names>W</given-names></name>
<name><surname>Matzuk</surname><given-names>MM</given-names></name>
<name><surname>Gordon</surname><given-names>HS</given-names></name>
</person-group>. <article-title>Immunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506</article-title>. <source>J Pharmacol Exp Ther</source>. <year>1999</year>, <volume>289</volume>: <fpage>1202</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr15-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gold</surname><given-names>BG</given-names></name>
<name><surname>Udina</surname><given-names>E</given-names></name>
<name><surname>Bourdette</surname><given-names>D</given-names></name>
<name><surname>Navarro</surname><given-names>X</given-names></name>
</person-group>. <article-title>Neuroregenerative and neuroprotective actions of neuroimmunophilin compounds in traumatic and inflammatory neuropathies</article-title>. <source>Neurol Res</source>. <year>2004</year>, <volume>26</volume>: <fpage>371</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr16-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gold</surname><given-names>BG</given-names></name>
<name><surname>Yew</surname><given-names>JY</given-names></name>
<name><surname>Zeleny-Pooley</surname><given-names>M</given-names></name>
</person-group>. <article-title>The immunosuppressant FK506 increases GAP-43 mRNA levels in axotomized sensory neurons</article-title>. <source>Neurosci Lett</source>. <year>1998</year>, <volume>241</volume>: <fpage>25</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr17-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grand</surname><given-names>AG</given-names></name>
<name><surname>Myckatyn</surname><given-names>TM</given-names></name>
<name><surname>Mackinnon</surname><given-names>SE</given-names></name>
<name><surname>Hunter</surname><given-names>DA</given-names></name>
</person-group>. <article-title>Axonal regeneration after cold preservation of nerve allografts and immunosuppression with tacrolimus in mice</article-title>. <source>J Neurosurg</source>. <year>2002</year>, <volume>96</volume>: <fpage>924</fpage>–<lpage>32</lpage>.</citation>
</ref>
<ref id="bibr18-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hontanilla</surname><given-names>B</given-names></name>
<name><surname>Aubá</surname><given-names>C</given-names></name>
<name><surname>Arcocha</surname><given-names>J</given-names></name>
<name><surname>Gorría</surname><given-names>O</given-names></name>
</person-group>. <article-title>Nerve regeneration through nerve autografts and cold preserved allografts using tacrolimus (FK506) in a facial paralysis model: a topographical and neurophysiological study in monkeys</article-title>. <source>Neurosurgery</source>. <year>2006</year>, <volume>58</volume>: <fpage>768</fpage>–<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr19-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hudak</surname><given-names>PL</given-names></name>
<name><surname>Amadio</surname><given-names>PC</given-names></name>
<name><surname>Bombardier</surname><given-names>C</given-names></name>
</person-group>. <article-title>Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand)</article-title>. <source>Am J Ind Med</source>. <year>1996</year>, <volume>29</volume>: <fpage>602</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr20-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jester</surname><given-names>A</given-names></name>
<name><surname>Harth</surname><given-names>A</given-names></name>
<name><surname>Wind</surname><given-names>G</given-names></name>
<name><surname>Germann</surname><given-names>G</given-names></name>
<name><surname>Sauerbier</surname><given-names>M</given-names></name>
</person-group>. <article-title>Disabilities of the arm, shoulder and hand (DASH) questionnaire: determining functional activity profiles in patients with upper extremity disorders</article-title>. <source>J Hand Surg Br</source>. <year>2005</year>, <volume>30</volume>: <fpage>23</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr21-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jifeng</surname><given-names>H</given-names></name>
<name><surname>Dezhong</surname><given-names>L</given-names></name>
<name><surname>Qiongjiao</surname><given-names>Y</given-names></name>
<name><surname>Huayong</surname><given-names>Z</given-names></name>
<name><surname>Shipu</surname><given-names>L</given-names></name>
</person-group>. <article-title>Evaluation of PRGD/FK506/NGF conduits for peripheral nerve regeneration in rats</article-title>. <source>Neurol India</source>. <year>2010</year>, <volume>58</volume>: <fpage>384</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr22-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Konofaos</surname><given-names>P</given-names></name>
<name><surname>Burns</surname><given-names>J</given-names></name>
<name><surname>Terzis</surname><given-names>JK</given-names></name>
</person-group>. <article-title>Effect of low-dose FK506 after contralateral C7 transfer to the musculocutaneous nerve: a study in rats</article-title>. <source>J Reconstr Microsurg</source>. <year>2010</year>, <volume>26</volume>: <fpage>225</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr23-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>M</given-names></name>
<name><surname>Doolabh</surname><given-names>VB</given-names></name>
<name><surname>Mackinnon</surname><given-names>SE</given-names></name>
<name><surname>Jost</surname><given-names>S</given-names></name>
</person-group>. <article-title>FK506 promotes functional recovery in crushed rat sciatic nerve</article-title>. <source>Muscle Nerve</source>. <year>2000</year>, <volume>23</volume>: <fpage>633</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr24-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lundborg</surname><given-names>G</given-names></name>
</person-group>. <article-title>A 25-year perspective of peripheral nerve surgery: evolving neuroscientific concepts and clinical significance</article-title>. <source>J Hand Surg Am</source>. <year>2000</year>, <volume>25</volume>: <fpage>391</fpage>–<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr25-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martin</surname><given-names>D</given-names></name>
<name><surname>Pinsolle</surname><given-names>V</given-names></name>
<name><surname>Merville</surname><given-names>P</given-names></name>
<name><surname>Moreau</surname><given-names>K</given-names></name>
<name><surname>Pelissier</surname><given-names>P</given-names></name>
<name><surname>Baudet</surname><given-names>J</given-names></name>
</person-group>. <article-title>Premier cas mondial d’autoréimplantation de membre associé à un traitement immunosuppresseur (FK 506-Tacrolimus®): rapport préliminaire à 18 mois</article-title>. <source>Ann Chir Plast Esthet</source>. <year>2005</year>, <volume>50</volume>: <fpage>257</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr26-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mowlavi</surname><given-names>A</given-names></name>
<name><surname>Ghavami</surname><given-names>A</given-names></name>
<name><surname>Song</surname><given-names>YH</given-names></name>
<name><surname>Neumeister</surname><given-names>M</given-names></name>
</person-group>. <article-title>Limited use of cyclosporin A in skeletal muscle ischemia–reperfusion injury</article-title>. <source>Ann Plast Surg</source>. <year>2001</year>, <volume>46</volume>: <fpage>426</fpage>–<lpage>30</lpage>.</citation>
</ref>
<ref id="bibr27-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muthuraman</surname><given-names>A</given-names></name>
<name><surname>Sood</surname><given-names>S</given-names></name>
</person-group>. <article-title>Pharmacological evaluation of tacrolimus (FK-506) on ischemia reperfusion induced vasculatic neuropathic pain in rats</article-title>. <source>J Brachial Plex Peripher Nerve Inj</source>. <year>2010</year>, <volume>5</volume>: <fpage>13</fpage>.</citation>
</ref>
<ref id="bibr28-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Napier</surname><given-names>JR</given-names></name>
</person-group>. <article-title>The significance of Tinel’s sign in peripheral nerve injuries</article-title>. <source>Brain</source> <year>1949</year>, <volume>72</volume>: <fpage>63</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr29-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Navarro</surname><given-names>X</given-names></name>
<name><surname>Udina</surname><given-names>E</given-names></name>
<name><surname>Ceballos</surname><given-names>D</given-names></name>
<name><surname>Gold</surname><given-names>BG</given-names></name>
</person-group>. <article-title>Effects of FK506 on nerve regeneration and reinnervation after graft or tube repair of long nerve gaps</article-title>. <source>Muscle Nerve</source>. <year>2001</year>, <volume>24</volume>: <fpage>905</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr30-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rustemeyer</surname><given-names>J</given-names></name>
<name><surname>Dicke</surname><given-names>U</given-names></name>
</person-group>. <article-title>Allografting combined with systemic FK506 produces greater functional recovery than conduit implantation in a rat model of sciatic nerve injury</article-title>. <source>J Reconstr Microsurg</source>. <year>2010</year>, <volume>26</volume>: <fpage>123</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr31-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rustemeyer</surname><given-names>J</given-names></name>
<name><surname>Krajacic</surname><given-names>A</given-names></name>
<name><surname>Dicke</surname><given-names>U</given-names></name>
</person-group>. <article-title>Histomorphological and functional impacts of postoperative motor training in rats after allograft sciatic nerve transplantation under low-dose FK 506</article-title>. <source>Muscle Nerve</source>. <year>2009</year>, <volume>39</volume>: <fpage>480</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr32-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schuind</surname><given-names>F</given-names></name>
<name><surname>Van Holder</surname><given-names>C</given-names></name>
<name><surname>Mouraux</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>The first Belgian hand transplantation – 37 month term results</article-title>. <source>J Hand Surg Br</source>. <year>2006</year>, <volume>31</volume>: <fpage>371</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr33-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schuind</surname><given-names>F</given-names></name>
<name><surname>Abramowicz</surname><given-names>D</given-names></name>
<name><surname>Schneeberger</surname><given-names>S</given-names></name>
</person-group>. <article-title>Hand transplantation: the state-of-the-art</article-title>. <source>J Hand Surg Eur</source>. <year>2007</year>, <volume>32</volume>: <fpage>2</fpage>–<lpage>17</lpage>.</citation>
</ref>
<ref id="bibr34-1753193411427826">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Schuind</surname><given-names>F</given-names></name>
<name><surname>Phan</surname><given-names>DQD</given-names></name>
<name><surname>Cermak</surname><given-names>K</given-names></name>
<name><surname>El Kazzi</surname><given-names>W</given-names></name>
<name><surname>Bahm</surname><given-names>J</given-names></name>
</person-group>. <article-title>Stimulation biologique de la régénération axonale</article-title>. In: <person-group person-group-type="editor">
<name><surname>Fontaine</surname><given-names>C</given-names></name>
<name><surname>Liverneaux</surname><given-names>P</given-names></name>
<name><surname>Masmejean</surname><given-names>E</given-names></name>
</person-group> (eds) <source>Cours européen de pathologie chirurgicale du membre supérieur et de la main 2011</source>. <publisher-loc>Montpellier</publisher-loc>: <publisher-name>Sauramps</publisher-name>, <year>2011</year>: <fpage>407</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr35-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sharkey</surname><given-names>J</given-names></name>
<name><surname>Butcher</surname><given-names>SP</given-names></name>
</person-group>. <article-title>Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia</article-title>. <source>Nature</source>. <year>1994</year>, <volume>371</volume>: <fpage>336</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr36-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Snyder</surname><given-names>AK</given-names></name>
<name><surname>Fox</surname><given-names>IK</given-names></name>
<name><surname>Nichols</surname><given-names>CM</given-names></name>
<etal/>
</person-group>. <article-title>Neuroregenerative effects of preinjury FK-506 administration</article-title>. <source>Plast Reconstr Surg</source>. <year>2006</year>, <volume>118</volume>: <fpage>360</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr37-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sunderland</surname><given-names>S</given-names></name>
</person-group>. <article-title>Rate of regeneration in human peripheral nerves; analysis of the interval between injury and onset of recovery</article-title>. <source>Arch Neurol Psychiatry</source>. <year>1947</year>, <volume>58</volume>: <fpage>251</fpage>–<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr38-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Terzis</surname><given-names>JK</given-names></name>
<name><surname>Konofaos</surname><given-names>P</given-names></name>
</person-group>. <article-title>Low-dose FK506 after contralateral C7 transfer to the musculocutaneous nerve using two different tubes: a study in rats</article-title>. <source>Ann Plast Surg</source>. <year>2010</year>, <volume>64</volume>: <fpage>622</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr39-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tinel</surname><given-names>J</given-names></name>
</person-group>. <article-title>Le signe du fourmillement dans les lésions des nerfs périphériques</article-title>. <source>Presse Médicale</source>. <year>1915</year>, <volume>47</volume>: <fpage>388</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr40-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Udina</surname><given-names>E</given-names></name>
<name><surname>Ceballos</surname><given-names>D</given-names></name>
<name><surname>Verdú</surname><given-names>E</given-names></name>
<name><surname>Gold</surname><given-names>BG</given-names></name>
<name><surname>Navarro</surname><given-names>X</given-names></name>
</person-group>. <article-title>Bimodal dose-dependence of FK506 on the rate of axonal regeneration in mouse peripheral nerve</article-title>. <source>Muscle Nerve</source>. <year>2002</year>, <volume>26</volume>: <fpage>348</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr41-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Udina</surname><given-names>E</given-names></name>
<name><surname>Gold</surname><given-names>BG</given-names></name>
<name><surname>Navarro</surname><given-names>X</given-names></name>
</person-group>. <article-title>Comparison of continuous and discontinuous FK506 administration on autograft or allograft repair of sciatic nerve resection</article-title>. <source>Muscle Nerve</source>. <year>2004</year>, <volume>29</volume>: <fpage>812</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr42-1753193411427826">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yildirim</surname><given-names>FB</given-names></name>
<name><surname>Sarikcioglu</surname><given-names>L</given-names></name>
<name><surname>Ozsoy</surname><given-names>U</given-names></name>
<name><surname>Demir</surname><given-names>N</given-names></name>
<name><surname>Demirtop</surname><given-names>A</given-names></name>
<name><surname>Ucar</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Effect of FK506 administration after obturator nerve injury: a functional and ultrastructural study</article-title>. <source>Acta Neurobiol Exp (Wars)</source>. <year>2008</year>, <volume>68</volume>: <fpage>477</fpage>–<lpage>83</lpage>.</citation>
</ref>
<ref id="bibr43-1753193411427826">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Zochodne</surname><given-names>DW</given-names></name>
</person-group>. <source>Neurobiology of peripheral nerve regeneration</source>. <publisher-loc>Cambridge</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>, <year>2008</year>.</citation>
</ref>
</ref-list>
</back>
</article>